Thymogen vs thymosin alpha 1: compare structure, dosing, half-life, regulatory status, and research uses of these two very different thymic peptides.
Thymogen and thymosin alpha 1 are not the same peptide, even though both are discussed as thymic immune modulators. Thymogen is a synthetic dipeptide made of glutamic acid and tryptophan, while thymosin alpha 1 (Tα1) is a 28-amino-acid peptide cut from the larger protein prothymosin alpha. They differ in size, half-life, approved uses, and dosing, so treating them as interchangeable is a mistake.
Quick Comparison of Thymogen and Thymosin Alpha 1
The table below summarizes the differences that matter most to researchers, clinicians, and readers trying to tell the two apart.
| Feature | Thymogen | Thymosin Alpha 1 |
|---|---|---|
| Chemical class | Synthetic dipeptide (Glu-Trp) | 28-amino-acid peptide |
| Molecular weight | About 333 Da | About 3,108 Da |
| Origin | Synthetic, based on thymic peptide research | Cleaved from prothymosin alpha |
| Common brand name | Thymogen | Zadaxin |
| Typical research dose | 0.1 mg intranasal or intramuscular | 1.6 mg subcutaneously, twice weekly |
| Half-life | Minutes | Roughly 2 hours |
| FDA-approved in the US | No | No |
| Approved elsewhere | Limited, mainly Eastern Europe | Approved in 30+ countries |
Chemical Structure and Origin
Thymogen is a two-amino-acid chain, glutamyl-tryptophan, that was designed to mimic a small piece of thymic hormone activity. Because it is so small, it is cheap to synthesize and easy to deliver through the nose or by injection. Its simplicity is also its limitation: a dipeptide carries far less structural information than a full peptide hormone.
Thymosin alpha 1 is a fragment of prothymosin alpha, a protein found in many tissues, not just the thymus. The active 28-mer was isolated and then produced synthetically for clinical use. Its larger size gives it more contact points with immune receptors, which is one reason its research profile looks so different from Thymogen's.
How Each Peptide Behaves in the Body
- Stability: Thymogen is broken down within minutes, so frequent or intranasal dosing is common in the studies that use it.
- Exposure: Thymosin alpha 1 circulates longer after subcutaneous injection, which supports twice-weekly dosing in published trials.
- Immune signaling: Thymosin alpha 1 has been studied for T-cell maturation, natural killer cell activity, and Toll-like receptor signaling.
- Thymogen activity: Thymogen has been explored for similar immune endpoints, but the published data are older and mostly non-English.
Regulatory Status and Clinical Evidence
Thymosin alpha 1 has the stronger clinical record of the two. Synthetic Tα1 is manufactured as Zadaxin and approved in more than 30 countries for chronic hepatitis B and C, and it is used as an adjuvant in some cancer immunotherapy protocols. Thymosin alpha 1 is not FDA-approved for human use in the United States, where it is sold only as a research chemical.
Reported thymosin alpha 1 benefits in clinical research center on improved immune response in hepatitis and selected oncology settings, but results vary by condition and study design. The peptide is not a cure for any disease, and regulators have not cleared it for general immune support.
Thymogen sits in a much thinner evidence base. Most human data come from small studies in Russia and neighboring countries, and Western regulators have not reviewed it for approval. That gap matters when comparing the two compounds.
Dosing, Safety, and Practical Considerations
A thymosin alpha 1 dosage chart drawn from published trials typically lists 1.6 mg given subcutaneously twice weekly, often for six to twelve months depending on the condition. Thymogen protocols usually list 0.1 mg per dose, delivered intranasally or by intramuscular injection, sometimes on alternating days.
The most common thymosin alpha 1 side effects reported in trials are mild: injection-site reactions, fatigue, and occasional low-grade fever. Thymogen is generally described as well tolerated in the limited literature, but long-term safety data are sparse for both peptides.
Neither peptide replaces standard medical care, and anyone considering them should discuss risks, interactions, and monitoring with a licensed healthcare professional.
Where They Fit Among Other Thymic Peptides
Researchers comparing thymosin alpha 1 vs thymosin beta 4 are looking at two very different molecules: beta 4 is a 43-amino-acid peptide studied mainly for cell migration, wound repair, and actin regulation rather than immune signaling.
In the same way, thymosin alpha 1 vs tb500 comparisons usually contrast immune modulation with tissue repair, since TB-500 is a synthetic fragment of thymosin beta 4 rather than a thymic immune peptide. Thymalin vs thymosin alpha 1 is another frequent pairing, because thymalin is a mixed bovine thymus extract while Tα1 is a single defined sequence.
Thymosin alpha 1 vs thymulin also comes up often, and it is essentially a size comparison: a 28-amino-acid peptide against a short zinc-dependent nonapeptide. Each compound has its own dosing, stability, and research history, so blanket statements about "thymic peptides" hide more than they reveal.
Bottom Line
- Thymogen is a synthetic Glu-Trp dipeptide, and thymosin alpha 1 is a 28-amino-acid peptide from prothymosin alpha.
- Thymosin alpha 1 has far more published clinical data and is approved in dozens of countries outside the US.
- Neither Thymogen nor thymosin alpha 1 is FDA-approved for human use in the United States.
- Half-life, dosing, and route of administration differ sharply between the two peptides.
- Anyone considering either compound should consult a healthcare professional before use.
Frequently Asked Questions
Is thymogen the same as thymosin alpha 1?
No. Thymogen is a synthetic glutamyl-tryptophan dipeptide, while thymosin alpha 1 is a 28-amino-acid peptide derived from prothymosin alpha. They have different molecular weights, half-lives, dosing schedules, and clinical histories, so they should not be treated as interchangeable.
Is thymosin alpha 1 FDA-approved?
Thymosin alpha 1 is not FDA-approved for any human use in the United States. It is manufactured as Zadaxin and approved in more than 30 other countries for conditions such as chronic hepatitis B and C. In the US it is sold only as a research chemical, which means there is no regulatory oversight of purity, potency, or dosing.
What dose of thymosin alpha 1 is used in studies?
Most published trials use 1.6 mg injected subcutaneously twice weekly, often for six to twelve months depending on the condition being studied. Doses are not standardized across all research settings, and self-dosing without medical supervision carries real risk.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.